| Market Cap | 286.62M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -19.79M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 16.00% |
| Sales | 10.32M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 80.00% |
| Dividend | N/A | Price/Book | 6.08 | EPS next 5Y | - | 52W High Chg | -7.00% |
| Recommedations | - | Quick Ratio | 5.98 | Shares Outstanding | 2.02B | 52W Low Chg | 299.00% |
| Insider Own | 8.98% | ROA | -25.97% | Shares Float | 1.79B | Beta | 2.86 |
| Inst Own | 16.30% | ROE | -38.95% | Shares Shorted/Prior | -/- | Price | 0.14 |
| Gross Margin | 87.27% | Profit Margin | -191.78% | Avg. Volume | 56,575 | Target Price | - |
| Oper. Margin | -200.92% | Earnings Date | Aug 28 | Volume | 33,000 | Change | 7.54% |
ImpediMed Limited, a medical technology company, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices in the Unites States and Europe. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema and deliver snapshot of fluid status and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-car body composition analysis; and HF-Dex analysis for point-or care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company was incorporated in 1999 and is headquartered in Carlsbad, California.